Tomiko Sunaga1, Brian Cicali2, Stephan Schmidt2, Joshua Brown3. 1. Center for Drug Evaluation and Safety, Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville, FL, United States; Showa University, School of Pharmacy, Tokyo, Japan. 2. Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, University of Florida College of Pharmacy, Orlando, FL, United States. 3. Center for Drug Evaluation and Safety, Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville, FL, United States. Electronic address: Joshua.brown@ufl.edu.
Abstract
OBJECTIVE: To estimate associations between contraceptive failures and concomitant CYP3A4-inducing medications by route of administration. STUDY DESIGN: Comparison of unintended pregnancy outcomes within U.S. Food and Drug Administration's Adverse Event Reporting System by couse of CYP3A4-inducing drugs and route of administration for levonorgestrel and etonogestrel/desogestrel. RESULTS: Among 14,504 levonorgestrel case reports, the reporting odds ratio (ROR) was increased for oral (ROR = 4.2 [3.0-5.7]), implants (ROR = 8.0 [5.8-11.0]), but not intrauterine (ROR = 0.9 [0.6-1.3]) levonorgestrel products. For 9348 etonogestrel/desogestrel case reports, oral and vaginal products were not associated with contraceptive failure. Etonogestrel containing implants (ROR = 4.9 [4.1-5.9]) were associated with increased contraceptive failure. CONCLUSION: Levonorgestrel containing combination oral products and implants containing levonorgestrel or etonogestrel were prone to CYP3A4-inducing drug-drug interactions that may increase contraceptive failures. IMPLICATIONS: The progestin components of hormonal contraceptives are susceptible to drug-drug interactions, but this susceptibility is influenced by route of administration. This study provides evidence from an Adverse Event Reporting System that CYP3A4-inducing medications increase the risk of unintended pregnancy for oral and implant contraceptives but not intrauterine or vaginal devices.
OBJECTIVE: To estimate associations between contraceptive failures and concomitant CYP3A4-inducing medications by route of administration. STUDY DESIGN: Comparison of unintended pregnancy outcomes within U.S. Food and Drug Administration's Adverse Event Reporting System by couse of CYP3A4-inducing drugs and route of administration for levonorgestrel and etonogestrel/desogestrel. RESULTS: Among 14,504 levonorgestrel case reports, the reporting odds ratio (ROR) was increased for oral (ROR = 4.2 [3.0-5.7]), implants (ROR = 8.0 [5.8-11.0]), but not intrauterine (ROR = 0.9 [0.6-1.3]) levonorgestrel products. For 9348 etonogestrel/desogestrel case reports, oral and vaginal products were not associated with contraceptive failure. Etonogestrel containing implants (ROR = 4.9 [4.1-5.9]) were associated with increased contraceptive failure. CONCLUSION:Levonorgestrel containing combination oral products and implants containing levonorgestrel or etonogestrel were prone to CYP3A4-inducing drug-drug interactions that may increase contraceptive failures. IMPLICATIONS: The progestin components of hormonal contraceptives are susceptible to drug-drug interactions, but this susceptibility is influenced by route of administration. This study provides evidence from an Adverse Event Reporting System that CYP3A4-inducing medications increase the risk of unintended pregnancy for oral and implant contraceptives but not intrauterine or vaginal devices.
Authors: Mohammad Akbar; Erin Berry-Bibee; Diana L Blithe; Ruth S Day; Alison Edelman; Joachim Höchel; Roxanne Jamshidi; Myong-Jin Kim; Li Li; Vivek S Purohit; Jim A Turpin; Pamela E Scott; David G Strauss; Haiying Sun; Naomi K Tepper; Lei Zhang; Chongwoo Yu Journal: J Clin Pharmacol Date: 2018-08-24 Impact factor: 3.126
Authors: Kathryn M Curtis; Naomi K Tepper; Tara C Jatlaoui; Erin Berry-Bibee; Leah G Horton; Lauren B Zapata; Katharine B Simmons; H Pamela Pagano; Denise J Jamieson; Maura K Whiteman Journal: MMWR Recomm Rep Date: 2016-07-29
Authors: Chelsea B Polis; Sarah E K Bradley; Akinrinola Bankole; Tsuyoshi Onda; Trevor Croft; Susheela Singh Journal: Contraception Date: 2016-03-24 Impact factor: 3.375
Authors: Joshua Brown; Tamra Goodrow; Dan Hartman; Justin L Hay; Kevin Hershberger; Susan Hershenson; Douglas McNair; Bethany Matthews; Mark A Milad; Stephan Schmidt; Kirsten M Vogelsong; Ping Zhao Journal: Contracept X Date: 2022-01-30